LianBio, Inc. is a clinical-stage biopharmaceutical company focused on identifying, in-licensing and commercializing innovative therapies for underserved patient populations in Greater China and select Asian markets. Headquartered in Hong Kong with additional offices in the United States, LianBio leverages a specialized business model to partner with global drug developers and secure rights to late-stage assets that address high-unmet medical needs.
The company’s development and commercialization platform spans oncology, endocrine and metabolic disorders as well as supportive-care treatments. By targeting therapies that have completed proof-of-concept or later-stage clinical trials outside Asia, LianBio seeks to accelerate regulatory submissions and product launches in China, Taiwan, Hong Kong and other emerging markets. Key therapeutic areas include novel agents for cancer, rare diseases and complications arising from chemotherapy.
Since its founding in 2018, LianBio has negotiated multiple licensing agreements that grant it exclusive rights to advance development, regulatory approval and commercialization of partner assets in its territories. The company works closely with local regulatory authorities, including China’s National Medical Products Administration (NMPA), to tailor clinical trial strategies, manufacturing supply chains and market-entry plans. This localized expertise aims to shorten time-to-market and bring important new medicines to patients with limited treatment choices.
LianBio is led by a management team with extensive biopharmaceutical experience and regional insight. The company continues to build its pipeline through collaborations with innovation-driven pharmaceutical and biotechnology firms, while expanding its commercial infrastructure to support future product launches across Asia. Through this model, LianBio aspires to become a premier partner for global drug developers and a trusted source of advanced therapies in its target markets.
AI Generated. May Contain Errors.
